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San Francisco, California; and §Department of Mathematics, Washington State University, Pullman, WashingtonABSTRACT Kinesin superfamily motor proteins contain a structurally conserved loop near the ATP binding site, termed L5. The
function of L5 is unknown, although several drug inhibitors of the mitotic kinesin Eg5 bind to L5. We used electron paramagnetic
resonance spectroscopy (EPR) to investigate the function of L5 in Eg5. We site-speciﬁcally attached EPR probes to ADP, L5,
and the neck linker element that docks along the enzymatic head to drive forward motility on microtubules (MTs). Nucleotide-
dependent spectral mobility shifts occurred in all of these structural elements, suggesting that they undergo coupled conforma-
tional changes. These spectral shifts were altered by deletion of L5 or addition of S-trityl-L-cysteine (STLC), an allosteric inhibitor
that binds to L5. In particular, EPR probes attached to the neck linker of MT-bound Eg5 shifted to a more immobilized component
in the nucleotide-free state relative to the ADP-bound state, consistent with the neck linker docking upon ADP release. In
contrast, after L5 deletion or STLC addition, EPR spectra were highly immobilized in all nucleotide states. We conclude that
L5 undergoes a conformational change that enables Eg5 to bind to MTs in a pre-powerstroke state. Deletion or inhibition of
L5 with the small-molecule inhibitor STLC blocks this pre-powerstroke state, forcing the Eg5 neck linker to dock regardless of
the nucleotide state.INTRODUCTIONEg5 is a homotetrameric kinesin motor that is vital to mitotic
spindle assembly. Small-molecule inhibitors of Eg5 cause
mitotic spindle disruption and initiate apoptosis in dividing
cells (1–3). Several of these inhibitors, including the drug
ispinesib, which is being tested in clinical trials, and the
compound S-trityl-L-cysteine (STLC), bind to the same
high-affinity site on Eg5 (4,5). This site is a unique surface
loop of unknown function called L5 (human Eg5 residues
116–133; Fig. 1 A).
In all kinesins, the a2 helix immediately follows the
GXXGXGKS/T nucleotide-binding P-loop element. L5 is
a structurally conserved loop found in all members of the
kinesin superfamily that breaks a2 after five residues; a2
reforms after L5 and extends down the length of the kinesin
head. L5 sequences vary among kinesin families in both
amino acid content and length. Eg5 is a member of the kine-
sin-5 family, which have the longest L5 sequences of ~15–20
residues (6).
L5 is a unique feature of kinesin motors and is not found in
either myosin motors or G proteins. However, a structural
comparison of kinesins, myosins, and G proteins reveals
a potential role for L5. In myosin motors, the 25/50-kDa
loop, which controls the rate of ADP release as well as entry
into the latch state, is located 15 residues C-terminal to its
GXXGXGKS/T P-loop. This location is 10 residues beyond
the location of L5 in the kinesins (7,8). The a1 helix in G
proteins, which corresponds structurally to a2 in kinesins,
breaks at approximately the position of L5 and leads directlySubmitted December 10, 2009, and accepted for publication March 9, 2010.
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0006-3495/10/06/2619/9 $2.00into Switch I, which controls the rate of GDP release (9).
These comparisons suggest that L5 in kinesins may control
conformational changes associated with ADP release.
Surprisingly, though, replacement or deletion of several
residues within L5 only modestly decreases ATPase activity
in standard assays (10).
Despite the fact that L5 deletions have little apparent
effect, kinetic data suggest a role for L5 in microtubule
(MT)-stimulated ADP release. After it collides with the
MT, the Eg5 head undergoes a slow kinetic isomerization
(~1 s1) (11). The structural changes corresponding to this
isomerization are unknown, but this step allows Eg5 to
bind tightly to the MT and release ADP to proceed through
its MT-stimulated ATPase cycle. Eg5 monomers and dimers
alike must undergo the isomerization step before MT-stimu-
lated ADP release occurs, suggesting that the isomerization
involves a conformational shift in the Eg5 head, possibly
in the neck linker and/or in L5 (11,12).
Small-molecule inhibitors that bind to L5 induce two
notable changes in Eg5. First, they increase the ADP affinity
of Eg5 heads, perhaps by interfering with the isomerization
step described above (13). Second, the inhibitor monastrol
has been shown to force the neck linker element (residues
354–367), which drives forward motility in kinesins, to
dock along the enzymatic core of Eg5 in a post-powerstroke
conformation (10). The combination of these two effects is
perplexing because the neck linker of ADP-bound Eg5 in
the absence of inhibitors is not fully docked, either in
solution or on MTs (10,14). Rather, the neck linker of ADP-
bound Eg5 is believed to be in a pre-powerstroke conforma-
tion that is roughly perpendicular to the axis of the Eg5 head
on the MT (14,15). These data have led to the idea thatdoi: 10.1016/j.bpj.2010.03.014
FIGURE 1 EPR probes, probe locations, and a model
based on this study. (A) Structure of Eg5 head showing
EPR probe locations. Alignment of PDB ID No. 2gm1
(34) and 1ii6 (15), rendered using PyMol Software (Schro-
dinger, LLC, New York, NY). ADP is shown in CPK
format with ribose oxygens labeled, the a3 helix and
Switch I elements are blue, and L5 is red except for the
seven residues that were deleted in the DL5 constructs,
which are shown in green. Added cysteines are indicated
in orange CPK format. The two structures have distinct
neck linker positions (circled in solid and dashed lines
for 2gm1 and 1ii6, respectively), and the positions of the
L360C and V365C mutations are shown in both structures.
The 1ii6 neck linker, with the labeled cysteines, is in
a perpendicular conformation and the 2gm1 neck linker
is docked. (B) Structures of the EPR probes and STLC
drug used. (C) Schematic diagram of conformational
changes in Eg5-367. Eg5 heads are shown bound to the
MT (blue) and free (red). The MT is gray, with plus and
minus ends indicated. L5 and the neck linker elements
are labeled, ADP is indicated as a red oval with D, and
ATP is indicated as a yellow oval with T. State 1 shows
two different conformations for Eg5 bound to ADP in
solution. The neck linker position is not sensitive to the
nucleotide state, whereas the L5 element is mobile in one
of these conformations and rigid in the other. The rigid
L5 conformation supports MT binding. Once ADP-bound
Eg5 binds to the MT, its neck linker adopts the perpendic-
ular conformation while L5 remains rigid (state 2). ADP release results in neck linker docking (state 3). Upon ATP binding, L5 returns to the more mobile
conformation whereas the neck linker remains docked (state 4). Evidence for and implications of this model are discussed in the text.
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an off-pathway conformation having both high ADP affinity
and a docked neck linker. However, it is unclear how a small
molecule binding to L5 would induce this state.
Here we use EPR spectroscopy to investigate conforma-
tional changes of the nucleotide pocket, L5, and the neck
linker of Eg5. Our data are consistent with a model in which
L5 and the neck linker undergo a series of coupled conforma-
tional changes that integrate into the stepping mechanism of
Eg5 (Fig. 1 C).
MATERIALS AND METHODS
Cloning
Eg5-367 in the pRSET plasmid (Invitrogen, Carlsbad, CA) encodes the first
367 amino acids of Eg5 with a C-terminal 6X histidine tag. For cys-light Eg5,
all native cysteines were replaced with alanine. Removal of native cysteines
and introduction of cysteines into cys-light Eg5 for MSL labeling was per-
formed via Quikchange site-directed mutagenesis (Stratagene, La Jolla,
CA). Eg5-513 was cloned from the MegaMan human transcriptome library
(Stratagene), and a C-terminal 6X-histidine tag was introduced by polymerase
chain reaction. TheDL5 mutants (lacking L5) were created using Exsite muta-
genesis (Stratagene). All constructs were verified by DNA sequencing.
Expression and protein puriﬁcation
All Eg5 constructs were grown and expressed in E. coli as described previ-
ously (16). Cells were resuspended in 20 mL of lysis buffer (10 mM Hepes,
2 mM MgCl2, 5 mM NaCl, 1 mM EGTA, 20 mM imidizole, 5 mM b-mercap-
toethanol, leupeptin (1 mg/mL), pepstatin (1 mg/mL), aprotinin (1 mg/mL),
phenylmethanesulfonyl fluoride (10 mg/mL), 5% sucrose, pH 6.8) and lysed
by French press. Supernatants were batch bound in Ni-NTA resin (Qiagen,Biophysical Journal 98(11) 2619–2627Valencia, CA) for 1 h, washed with lysis buffer containing 75 mM imidizole,
and eluted with lysis buffer containing 350 mM imidizole. Peak fractions
were dialyzed into lysis buffer with 1 mM DTT and 10 mM ATP, and then
applied to a 5 mL HiTrap S-Sepharose column (GE Healthcare, Waukesha,
WI) and eluted using a linear 5–500 mM NaCl gradient. Peak fractions
were pooled and frozen with an additional 15% sucrose in liquid nitrogen.
Protein labeling for EPR spectroscopy
Purified Eg5 constructs were concentrated and exchanged into labeling buffer
(20 mM HEPES, 2 mM Mg(OAc)2, 20 mM KOAc, 1 mM EGTA, 5% sucrose,
pH 6.8, 4C). The protein was labeled at the nucleotide-binding site by addi-
tion of 70mM spin-labeled nucleotide analogs to 100 mM Eg5-367 in labeling
buffer. Nucleotide-analog spin probes were synthesized according to a
previously described protocol (17). The spin-labeled nucleotides 20-SLATP,
30-SLATP, and 20,30-SLATP all exchanged into the nucleotide pocket of Eg5-
367 in a few minutes 20,30-SLAMPPNP exchanged in after an overnight incu-
bation. The SLATP species are hydrolyzed by Eg5, resulting in Eg5SLADP
at the nucleotide site.
Covalent modification of single cysteine-containing Eg5 constructs was
carried out by addition of 300 mM 4-maleimido-2,2,6,6-tetramethyl-1-piper-
idinyloxy (MSL; Sigma Aldrich, St. Louis, MO) and 100 mM protein to the
labeling buffer. MSL labeling was allowed to proceed overnight at 4C.
The activities of Eg5-367, Eg5-367 DL5, and MSL-lableled proteins were
verified in a coupled-enzyme ATPase assay as described previously (16).
Sample preparation
Unreacted spin probe was removed using a P-30 spin column (Bio-Rad,
Hercules, CA) equilibrated with labeling buffer as described previously
(18). For experiments with the diphosphateAlF4 species at the active site,
10 mM NaF and 2 mM AlCl3 were subsequently added. Nucleotide-free
(apo) Eg5 was generated by incubating spin-labeled Eg5 with a solution of
2% apyrase (1 U/mL) for 15 min. The ADPase activity of apyrase was verified
by thin-layer chromatography, which showed that all ATP was converted to
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therefore, within the 15-min incubation period, essentially all Eg5 will be
nucleotide-free. For EPR spectra taken under crystallization conditions,
MSL-labeled Eg5 was exchanged into a buffer containing 18% polyethylene
glycol (PEG)-3350, 100 mM PIPES, and 200 mM NaNO3 pH 6.8 (15). Exper-
iments performed in the presence of STLC (Sigma Aldrich, St. Louis, MO) or
Monastrol (Sigma Aldrich) used a 2:1 molar excess of inhibitor over spin-
labeled Eg5 protein. Increasing the STLC concentration to a 4:1 molar excess
did not change the EPR spectra obtained from these proteins.
For spectral accumulation of Eg5 samples in solution, the protein was
loaded into a 25 mL quartz capillary. For the spectra of Eg5 bound to
MTs, 20 mM spin-labeled protein and 60 mM paclitaxel-stabilized, polymer-
ized MTs purified from porcine brain were added to the labeling buffer. For
MSL-labeled protein, either 2 mM ADP or ADPAlF4 was added to the
labeling buffer. For the apo state, apyrase-treated protein was used. The
MT-Eg5 solution was centrifuged at 100,000  g for 15 min. The pellet
was then scraped with a spatula onto a quartz flat cell, covered with a cover-
slip, sealed with vacuum grease, and placed in the EPR cavity as described
previously (18).EPR spectroscopy and data analysis
First-derivative, X-band EPR spectra were accumulated with a Bruker EMX
spectrometer (Bruker Instruments, Billerica, MA) using a high-sensitivity
microwave cavity. The instrument settings were as follows: microwave
power ¼ 25 mW, time constant ¼ 164 ms, frequency ¼ 9.83 GHz, and
modulation ¼ 0.1 mT at a frequency of 100 kHz. Spectral accumulation
and temperature control were performed as described previously (19). All
spectra were taken in 10-mT-wide sweeps.
Effective cone angles of mobility can be approximated using the order
parameter S ¼ (Tk0  T0)/(Tk  T0) as a measure of probe mobility. Here
2Tk0 is the observed splitting, 2Tk is the splitting for an immobilized probe
(7.16 mT for 20,30-SLADP), and 2T0 is the isotropic hyperfine splitting for
freely tumbling SLADP in solution (3.23 mT for 20,30-SLADP). The cone
angle is then given by cos q ¼ 0.5 5 0.5*(1 þ 8S)1/2, where 2q is the
vertex angle of the cone of mobility. For additional details, see Griffith
and Jost (20) and Alessi et al. (21), and Fig. S1 of the Supporting Material.
There is a small effect of polarity on the EPR spectra of nitroxide spin
probes, leading to a small change in the broadening of the spectrum (maxi-
mally ~0.1 mT) on going from the interior of a protein to an exposed, aqueous
environment (22). The nitroxide probes used in these studies are attached to
the ribose hydroxyls of the nucleotide or to solvent-exposed cysteine residues.
Available structural data on Eg5 and other kinesin-family motors all indicate
that the attached spin probe moieties would be solvent-exposed in both the
open and closed conformations of the nucleotide pocket (15,23–26), making
the above an overestimate of any polarity effects. However, still using this
maximum value, the result would be to underestimate the change in the
cone angle by 3–4. This is too small an effect to alter any of our conclusions.
Deconvolutions to determine the ratios of MSL probes in the more mobile
and more immobilized spectral components were performed using a Microsoft
Excel-based least-squares fitting algorithm as detailed previously (27).
For the mobile basis spectrum, we used the spectrum of MTE124C-
MSLADPAlF4 or, alternatively, that of E124C-MSLADP in solution.
For the immobilized basis spectrum, we used the spectrum of MTV365C-
MSL taken at 2C. The basis spectra and sample deconvolutions are shown
in Fig. S2. All deconvolutions produced c2 values % 2% using two basis
spectral components.RESULTS AND DISCUSSION
Site-speciﬁc introduction of EPR probes into Eg5
To determine the effects of L5 on nucleotide-dependent
conformational changes in Eg5, we performed EPR spectros-copy using spin probes located at several locations, either
attached to the ribose oxygens of ADP or covalently attached
to specific cysteines within a human monomeric Eg5
construct (Eg5-367; Fig. 1 A). To monitor conformational
changes in the nucleotide pocket, we used the synthetic
nucleotide spin probe 20,30-SLADP, as previously used for
kinesin-1 and ncd (18,24) (Fig. 1 B).
To generate a triphosphate or transition state analog, we
used ADPAlF4, as described in Materials and Methods.
We found that 20,30-SLADPAlF4 yielded similar spectral
components to 20,30-SLAMP-PNP. However, the ADPAlF4
bound far more tightly and thus revealed much clearer
spectra (data not shown).
To monitor conformational changes in L5 and the neck
linker, we used site-directed mutagenesis to remove and
replace all four native cysteines with alanines in Eg5-367.
Single cysteines were then added back for covalent modifica-
tion using MSL (Fig. 1 B, Materials and Methods). To conju-
gate probes to L5, we used an E124C mutant. For the neck
linker, we used L360C and V365C mutants.
Changes caused by deleting residues 125–131 from L5
(referred to here as L5 deletion or Eg5-367 DL5) (28) or
by adding the drug STLC were monitored at both the nucle-
otide pocket and the neck linker. Identical spectral shifts of
Eg5-367 bound to 20,30-SLADP were obtained using the
inhibitor monastrol (data not shown). However, STLC was
used for subsequent experiments because it is a single isomer
inhibitor (Fig. 1 B).
The maximal ATPase rate was 23.25 0.67 s1 for wild-
type Eg5-367 and 17 5 0.71 s1 for the Eg5-367 DL5
mutant, which is consistent with previous results (28). To
determine the activity of labeled Eg5-367, proteins were
labeled with MSL as described in Materials and Methods.
Double integration of EPR spectra verified that these
proteins were fully labeled. The maximal MT-stimulated
ATPase activities of labeled proteins were as follows:
E124C-MSL, 18.4 5 4.8; L360C-MSL, 17.7 5 1.2; and
V365C-MSL, 14.05 1.7 ATP/head/s. Thus, MSL labeling
appeared to have a relatively minor effect on ATPase
activity, as reported previously for small fluorescent probes
attached to monomeric Eg5 (14).L5 causes an immobilization of 20,30-SLADP
in the Eg5 nucleotide pocket that is blocked
by STLC treatment
We tested whether L5 has an effect on the conformation of the
nucleotide pocket of Eg5 in solution by comparing the EPR
spectra of 20,30-SLADP bound to Eg5-367 and Eg5-367
DL5 (Fig. 2 A). Fig. 2 A shows our basic observation. The
three sharp central spectral peaks in the spectra (denoted by
arrows) result from unbound probe that is rapidly tumbling
in solution. When 20,30-SLADP binds at the active site of
Eg5, the adjacent protein surface spatially restricts the probe’s
motion, resulting in a broadening of the EPR spectral peaks.Biophysical Journal 98(11) 2619–2627
FIGURE 2 20,30-SLADP bound to Eg5-367 reveals mixed nucleotide
pocket conformations in solution and on MTs. The innermost three sharp
peaks of all spectra are from 20,30-SLADP that is free in solution (denoted
by arrows). Insets show low-field spectral components, which are identified
here by number ([C#]), as described below. (A) Top: Spectra of 20,30-SLADP
bound to wild-type (black), DL5 (red), and STLC-treated Eg5-367 (blue)
reveal a common inner component ([C1]) at the same magnetic field loca-
tion. Bottom: Similar spectra of Eg5-36720,30-SLADPAlF4. Wild-type
Eg5-367 spectra show a more immobilized component ([C2]) that is not
present in STLC-treated and DL5 spectra. (B) When bound to MTs, 20,30-
SLADP bound to Eg5-367 and Eg5-367 DL5 reveal the same inner compo-
nent as in solution ([C1], coarse dashed line) as well as a broader component
([C4], fine dashed line). STLC-treated Eg5-367 displays an outward shift of
a single spectral component (component [C3]). (C) 20,30-SLADPAlF4
bound to Eg5-367 and Eg5-367 DL5 on MTs reveal identical two-compo-
nent spectra. The inner component has the same low- to high-field splitting
as STLC-treated MTEg5-36720,30-SLADP ([C3], solid line). The outer
component ([C5]) is from highly immobilized probes. The spectrum of
STLC-treated 20,30-SLADPAlF4 has a single component ([C4]) that is
more immobilized than 20,30-SLADP.
2622 Larson et al.This is visualized as a greater splitting between the low-field
peak and high-field dip components of the spectra (some of
which are denoted by solid or dashed vertical lines). The
more restricted the motion of the probe, the greater the low-
to high-field splitting (Table 1). The spectrum of Eg5-
36720,30-SLADP (Fig. 2 A, black) has two components.
There is a dominant low-field component (labeled [C1] in
the inset) in equilibrium with another component seen as
a low-field shoulder (labeled [C2] in the inset). The low- to
high-field splittings of the [C1] and [C2] components areBiophysical Journal 98(11) 2619–26274.69 and 6.12 mT, respectively. As a useful first approxima-
tion to relate the low- to high-field splitting in the magnetic
field variable to the physical magnitude of the conformational
change we are observing, EPR probe mobility can be modeled
as motion in a cone of revolution (20,21). For the [C1] and
[C2] components, these correspond to cones of mobility
with vertex angles of 120.5 and 71.5, respectively. We
present our data on the magnitudes of the low- to high-field
splittings both in mT and in terms of a cone angle through
which the probe can move freely (Table 1). The same two
spectral components were also visualized using the probes
20-SLADP and 30-SLADP (data not shown). Therefore, these
two components are not due to the two enantiomer positions
of the spin-label moiety on the ribose oxygens of 20,30-
SLADP. Rather, we conclude that they reflect two different
conformational states of the Eg5 protein that are detected by
the spin probes.
Eg5-367 DL5 and Eg5-367 treated with STLC completely
lacked the more immobilized spectral component ([C2],
71.5). The more mobile component ([C1], cone angle
120.5) remained unchanged (Fig. 2 A, red and blue
spectra). This result suggests that L5 induces an immobiliza-
tion of 20,30-SLADP bound to the nucleotide pocket that is
not observed after STLC treatment or deletion of residues
within L5. The spectral components of Eg5-367, Eg5-367
DL5, and STLC-treated Eg5-367 in solution with 20,30-
SLADPAlF4 at the active site were the same as those of
bound 20,30-SLADP (Fig. 2 A, bottom).
Our data indicate that the spin probe samples at least two
conformations of the Eg5 nucleotide site in solution, and at
least one of these conformations is L5-dependent. However,
the conformations detected by 20,30-SLADP are not nucleo-
tide-dependent. These two L5-dependent conformations of
the nucleotide pocket visualized by our EPR spectra may
reflect several different conformations in a mixed population
of Eg5-367ADP or Eg5-367ADPAlF4. Kinetic studies
on both Eg5 monomers and dimers have identified a confor-
mational change of L5 upon nucleotide binding in solution
(13,29). One of these two populations has high ADP affinity
and low MT affinity, whereas the other has high MT affinity
and low ADP affinity. The two visible components of 20,30-
SLADP in solution may reflect these two populations of
Eg5-367. To illustrate this idea, Fig. 1 C shows two confor-
mations of Eg5-367ADP in solution (state 1); the one with
a more immobilized L5 element binds to the MT (state 2).Spectra of MSL bound to the Eg5 neck linker do
not depend on the nucleotide state in solution
To identify conformational changes of the Eg5 neck linker
element in solution, MSL was covalently attached to residue
360 or 365 (L360C-MSL or V365C-MSL; positions shown
in Fig. 1 A). Unreacted MSL was removed by column puri-
fication (see Materials and Methods). Thus, in contrast to the
20,30-SLADP spectra, the three central peaks in the MSL
TABLE 1 Low-to-high ﬁeld splittings and cone angles of mobility for 20,30-SLADP bound to Eg5
Sample Splittings (mT) Cone angle ()
20,30-SLADP 20,30-SLADPAlF4 20,30-SLADP 20,30-SLADPAlF4
MT þMT MT þMT MT þMT MT þMT
Eg5-367 4.69, [C1] 4.78, [C1] 4.64, [C1] 5.07, [C3] 120.5 117.4 122.2 107.8
6.12, [C2] 5.57 [C4] 6.32, [C2] 6.83, [C5] 71.5 91.1 63.6 38.9
Eg5-367 DL5 4.69, [C1] 4.74, [C1] 4.71, [C1] 5.14, [C3] 120.5 118.8 119.8 105.5
5.52 [C4] 6.88, [C5] 92.8 35.8
Eg5-367 STLC 4.69, [C1] 4.97, [C3] 4.75, [C1] 5.44, [C4] 120.5 111.1 118.4 95.5
Splittings in mT are on the left, and cone angles of probe mobility corresponding to those splittings in degrees are on the right. Bracketed numbers next to
splittings indicate specific spectral components shown in the insets of Fig. 2. Standard errors of EPR splittings were5 0.03 mT. Sample-to-sample variation
in EPR splittings is on the order of 0.2 mT; therefore, splittings within 0.2 mT of each other are considered to be the same spectral component (denoted as [C1]–
[C5] in Fig. 2 and in this table) (24).
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Eg5. The EPR spectra of probes at both locations had two
spectral components that were not significantly affected by
a change in nucleotide state (Fig. 3 A) or by STLC treatment.
In addition, the spectra of V365C-MSL with and without
STLC were identical at 25C and 4C (Fig. 3 B). This result
indicates that STLC binding does not significantly alter the
change in free energy between the available neck linkerFIGURE 3 The neck linker position of Eg5 in solution does not depend on
the nucleotide state or STLC treatment. More-immobilized spectral compo-
nents are indicated with dashed lines, and the fraction of immobilized probes
is indicated to the right of each spectrum. (A) Both V365C-MSL (left) and
L360C-MSL (right) yield similar spectra in the presence of ADP and
ADPAlF4. V365C-MSL spectra shift to a more immobilized component
in crystallization buffer conditions (red). The addition of PEG to the motor
in solution is likely to induce this shift to the more-immobilized component.
Of importance, the sample for this spectrum is not an actual crystal; rather, it
is a sample of V365-MSL in a solution that generated crystals of Eg5 (15)
(see Materials and Methods). (B) STLC treatment does not alter the spectrum
of V365C-MSL in the presence of ADP at either 25C or 4C (left), indi-
cating that the free-energy changes between available neck linker conforma-
tions are not altered by STLC treatment. Spectra of L360C-MSL in the
presence of ADP at 25C (right) were also identical in the presence and
absence of STLC.conformations corresponding to the two spectral components
of V365C-MSL (30). Although it is possible that the Eg5
neck linker undergoes conformational changes that are not
visualized by MSL covalently bound to Eg5 at these loca-
tions, we note that Eg5 neck linker docking is resolvable
by EPR in the experiments described below. Thus, we
conclude that the simplest explanation for these data is that
neck linker docking of Eg5 in solution is not induced by
the addition of either ADPAlF4 or STLC. In our model,
the neck linker conformation of Eg5 in solution is decoupled
from its nucleotide state (shown in Fig. 1 C, state 1) and from
STLC binding.
The above data stand in apparent contrast to a previous x-
ray crystal structure (31) and to spectroscopic data showing
that the allosteric inhibitor monastrol induces Eg5 neck
linker docking in solution (10). To investigate this discrep-
ancy, we took EPR spectra of V365C-MSL under altered
buffer conditions. PEG has been shown to induce protein-
protein interactions in a large number of systems (32),
and is a component of some crystallization buffers used
for Eg5 (15,31). The addition of crystallization buffer
components containing PEG (15) (see Materials and
Methods for details) increased the fraction of probe in the
immobilized component by 20% (Fig. 3 A). This result
demonstrates that the neck linker of V365C-MSL is able
to dock in solution, but is not induced to do so by addition
of STLC. The free-energy change between conformational
states corresponding to the mobile and immobilized spectral
components is extremely small (~0.3 kJ/mol for V365C-
MSLADP in solution), so it is quite possible that the
neck linker conformation can be shifted by different buffer
conditions or by a slightly different drug agent binding to
Eg5. In support of this idea, a recent x-ray crystal structure
of Eg5 bound to STLC showed different neck linker confor-
mations for two Eg5 heads within the same crystal unit cell
(25). Similarly, kinesin-1 can be induced to dock its neck
linker by the mere addition of sulfate ions (27). We
conclude that the neck linker of Eg5 in solution may be
induced to dock by monastrol but is not induced to dock
by STLC, due either to a difference between these two allo-
steric inhibitors or to differences in experimental conditions
between past (10) and present experiments.Biophysical Journal 98(11) 2619–2627
2624 Larson et al.20,30-SLADP bound to the Eg5 nucleotide pocket
is immobilized upon binding of Eg5 to MTs
in the diphosphate state and further immobilized
in the triphosphate state
EPR spectra of 20,30-SLADP bound to kinesin-1 or ncd are
broadened upon binding of the MT and further broadened
upon binding of AlF4 on the MT. This broadening has
been attributed to a movement of Switch I toward the nucle-
otide pocket, referred to as closing of the nucleotide pocket
(24). This interpretation is supported by a cryo-electron
microscopy structure of MT-bound kinesin-1 (23). We
observed a similar phenomenon in Eg5. EPR spectroscopy
was performed on MTEg5-367 20,30-SLATP. MT-Eg5
pellets were prepared as described in Materials and Methods,
and elsewhere (18,24). The binding constant of Eg520,30-
SLADP to MTs was 2.6 mM (determined via sedimentation)
(11) and the concentration of MTs in the pellet was 700 mM.
Thus, <1% of the Eg5 in the pellet was not associated with
MTs. This is too small a value to affect our conclusions. The
resulting spectrum has multiple components, as seen in the
broad shoulder of the low-field peak and the broad high-field
dip (Fig. 2 B, black spectrum). The innermost component
has splitting identical to that of the inner, more mobile
component of the spectrum of Eg520,30-SLADP in solution
(component [C1], cone angle: 120.5; Fig. 2, A and B,
dashed vertical line). Upon MT binding, a significant
fraction of the probes shift to a new, more immobilized
component (component [C4]), with a corresponding cone
angle of mobility of 91.1. These data are consistent with
a fraction of motors adopting a more closed conformation
of the nucleotide pocket upon MT binding while in equilib-
rium with other motors that retain a more open conformation.
Of interest, the L5-dependent outer component (component
[C2]) of the spectrum of Eg5-36720,30-SLADP in solution
is lost upon MT binding, and the mobility of 20,30-SLADP
in the nucleotide pocket of the MTEg520,30-SLADP
state is not affected by deletion of L5 (Fig. 2 B, red versus
black spectra). The spectrum of the MTEg5-36720,30-
SLADPAlF4 state also has two components and is not
affected by deletion of L5 (Fig. 2 C, red versus black
spectra). The outermost spectral component (component
[C5]; Fig. 2 C) is very highly immobilized (cone angle:
38.9). These data are consistent with the idea that further
closing of the Eg5 nucleotide pocket occurs in the triphos-
phate state relative to the diphosphate state when the motor
is bound to MTs, as previously observed for kinesin and
ncd (24).
STLC treatment alters but does not prevent
MT-induced immobilization of an EPR probe
in the Eg5 nucleotide pocket
STLC treatment of Eg5-36720,30-SLADP resolves spectra
into one clear component, both in solution and when Eg5
is bound to MTs. In solution, the splitting of this componentBiophysical Journal 98(11) 2619–2627is identical to the inner, more mobile component of the spec-
trum of 20,30-SLADP bound to untreated Eg5 (component
[C1]; Fig. 2 A, blue spectrum). Several kinetic and spectro-
scopic studies have indicated that L5-binding drugs stabilize
a high-ADP-affinity state, radically slowing ADP product
release (10,13,26,33). The existence of a single spectral
component for STLC-treated Eg5 is consistent with the
idea that the conformational states reflected by the EPR spec-
trum in the presence of STLC together represent an open
state of the nucleotide pocket.
The binding of STLC-treated Eg5 to MTs induces a shift in
the spectrum of 20,30-SLADP to a more immobilized compo-
nent (component [C3], cone angle: 111.1; Fig. 2 B). This is
the same mobility seen in the inner spectral component of
MTEg5-36720,30-SLADPAlF4 (Fig. 2, B and C, solid
vertical line). This result indicates that STLC treatment of
MTEg5-36720,30-SLADP may cause the nucleotide
pocket to adopt an ATP-like conformation, consistent with
kinetic data showing that drugs that bind to L5 appear to
cause ATP resynthesis by Eg5 (13).
The single visible component in the spectrum of STLC-
treated Eg5-36720,30-SLADPAlF4 is not distinguishable
from component [C4] (cone angle: 95.5). This component
is more immobilized than component [C3] (cone angle:
111.1; Fig. 2, B and C, blue spectra). The trend of a shift
to a more immobilized component upon MT binding, and
again upon 20,30-SLADPAlF4 binding, is observed even
in STLC-treated Eg5. Thus, although the EPR spectra
suggest that STLC treatment alters the conformation of the
nucleotide pocket of Eg5 in all nucleotide states, it does
not prevent the MT- and ATP-induced probe immobilization
observed for untreated Eg5, kinesin, and ncd (24). We
conclude that STLC treatment of Eg5 does not block the
closing of Switch I around the nucleotide. In contrast to L5
deletion, STLC treatment markedly alters the spectra of
20,30-SLADP or 20,30-SLADPAlF4 bound to Eg5 on MTs.
STLC may exert additional effects on the nucleotide pocket
that are independent of L5. Consistent with this, a recent
x-ray crystal structure indicates that STLC may possibly alter
the Switch I/nucleotide state through contacts with the
a3-helix or the core b-sheet of Eg5 (25).MSL bound to L5 of Eg5 on MTs is moderately
immobilized in the ADP and apo states,
but is mobile in the triphosphate state
The above data indicate that L5 affects the conformation of
the nucleotide pocket in solution. To further examine L5
function, we sought to identify conformational changes
occurring in L5 as Eg5 binds to the MT, releases ADP,
and then binds ATP (Fig. 1 C). Eg5-367 was labeled with
MSL at a single cysteine at position 124 within L5
(E124C-MSL; Fig. 1 A). Spectra were collected from pellets
of E124C-MSLADP in solution and MTE124C-MSL in
the presence of ADP, in the apo state, and in the presence
FIGURE 4 L5 and neck linker movement is coupled to the Eg5 nucleotide state on MTs. All proteins are labeled with the MSL probe at the site indicated.
Nucleotide states are indicated to the left of each spectrum, and the fraction of immobilized probes is indicated to the right. Red spectra are in solution, black
spectra are MT-bound. (A) E124C, (B) L360C, (C) L360C DL5, (D) V365C, (E) V365C DL5, and (F) V365Cþ200 mM STLC.
L5 Establishes Eg5 Pre-Powerstroke State 2625of ADPAlF4. The spectrum of E124C-MSLADP in solu-
tion shows a vast majority of covalently attached probes
with high mobility (Fig. 4 A, three central peaks). For
MTE124C-MSLADP, 32% of probes are present in
a more immobilized component (dashed line). A similar
spectrum is observed in the MT-bound apo state, with 41%
of probes in the immobilized component. When Eg5 is
bound to MTs in the ADPAlF4 state, the EPR spectrum
again shows extremely mobile probes. We conclude that
the EPR spectra reveal a reversible conformational transition
of L5. Through this conformational transition, L5 may exert
an influence over the conformation of Eg5, particularly in the
ADP and apo states when bound to MTs. The conformation
of L5 observed for MTE124C-MSL in the ADP-bound and
apo states is referred to throughout the rest of the text as
‘‘rigid’’ to differentiate the L5 conformational change from
the separate, but correlated, closing of the nucleotide pocket
detected for MTEg5-36720,30-SLADP in the experiments
described above.MSL bound to the neck linker of Eg5 on MTs
is immobilized in the apo and triphosphate states
The Eg5 neck linker conformation has been shown to be
tightly coupled to the nucleotide state when the motor is
bound to MTs, transitioning between a conformation thatis believed to be roughly perpendicular to the MT axis (15)
and a conformation that is fully docked (14,34). We sought
to detect these changes by EPR spectroscopy using L360C-
MSL- and V365C-MSL-labeled Eg5. In the perpendicular
neck linker conformation, L360 is tucked against the head
and V365 is displaced away from it. In the docked neck
linker conformation, both residues are tucked against the
head (Fig. 1 A). All EPR spectra of both L360C-MSL and
V365C-MSL bound to MTs displayed an immobilized
component with a low- to high-field splitting of ~6.4 mT,
corresponding to a cone angle of ~60. The spectrum of
MTL360C-MSLADP has 61% of the probes in the more
immobilized component (Fig. 4 B). In contrast, the spectrum
of MTV365C-MSLADP shows only 22% of probes in the
more immobilized component (Fig. 4 D). The larger fraction
of more immobilized probes bound to L360 relative to V365
is consistent with the Eg5 neck linker adopting the perpen-
dicular conformation, or another conformation in which
L360 is docked against the core of Eg5 whereas V365 is
largely undocked (14,15) (depicted as state 2 in Fig. 1 C).
The spectrum of MTV365C-MSL undergoes a dramatic
shift to the more immobilized component in the apo state,
with 75% of probes in the more immobilized component
(Fig. 4 D). This is consistent with a transition from a perpen-
dicular neck linker conformation in the ADP state to a fully
docked conformation in the MT-bound apo state. Two piecesBiophysical Journal 98(11) 2619–2627
2626 Larson et al.of existing data support this interpretation. First, this exact
conformational transition of the Eg5 neck linker was
observed by means of fluorescence spectroscopy (14).
Second, the immobilization of neck linker-bound EPR
probes was shown to correlate with neck linker docking in
kinesin-1 (35). This transition is shown as state 3 in Fig. 1 C.
Very little additional immobilization occurs upon transi-
tion to the ADPAlF4 state, for either MTL360C-MSL
(76% of probes in the more immobilized component) or
MTV365C-MSL (81%) (Fig. 4, B and D). According to
the above interpretation, this result indicates that in the
majority of Eg5 motors, the neck linkers are fully docked
in the apo state and they remain docked in the triphos-
phate-analog state. Thus, the transition between the MT-
bound apo state and the MT-bound ADPAlF4 state induces
a rigid-to-mobile conformational transition in L5, but does
not affect the docked neck linker conformation. This is
depicted as state 4 in Fig. 1 C.MSL probes attached to the neck linker
of MT-bound Eg5-367 DL5 or STLC-treated
Eg5-367 are highly immobilized regardless
of nucleotide state
To establish whether there is a direct structural link between
L5 function and Eg5 neck linker conformation when bound
to MTs, EPR spectra were collected from L360C-MSL
(Fig. 4 C) and V365C-MSL (Fig. 4 E) using the Eg5-367
DL5 mutant. Spectra of MT-bound Eg5 with probes at
both locations show a large fraction of probes in the
more-immobilized component in all nucleotide states.
MTV365C-MSL DL5ADP has 85% of probes in the
more immobilized component, versus 22% for untreated
V365C-MSL with L5 intact. If our structural interpretation
of these EPR spectral data is correct, neck linker docking
is heavily favored for Eg5-367 DL5 in all nucleotide states
when bound to MTs.
Our spectra of STLC-treated MTEg5-36720,30-SLADP
are consistent with the idea that STLC induces an ATP-
like state of the Eg5 nucleotide pocket when bound to
MTs (33). To determine whether STLC induces an ATP-
like, fully docked state of the Eg5 neck linker when bound
to MTs, we collected EPR spectra from MT pellets of
STLC-treated V365C-MSL. Similar to the case with L5 dele-
tion, in the presence of STLC a large fraction of probes was
in the more-immobilized component in all nucleotide states
(Fig. 4 F). In particular, STLC-treated MTV365C-
MSLADP had 64% of probes in the immobilized compo-
nent versus 22% in the absence of STLC.
Although the effects of L5 deletion in STLC treatment that
we observed using 20,30- SLADP in the nucleotide pocket are
distinct, L5 deletion and STLC treatment also have a similar
effect on the neck linker. This functional defect prevents Eg5
from establishing its pre-powerstroke state by binding to
MTs with its neck linker in the perpendicular conformation.Biophysical Journal 98(11) 2619–2627Instead, the neck linker of Eg5-367 DL5 or Eg5-367 treated
with STLC is fully docked regardless of the nucleotide.CONCLUSIONS
This work demonstrates that L5 in the kinesin family
member Eg5 undergoes conformational changes that are
coupled to the nucleotide state and neck linker movement.
L5 causes a significant reduction in the mobility of a spin-
labeled ADP analog in the Eg5 nucleotide pocket. L5 itself
undergoes a nucleotide-dependent conformational change
when Eg5 is bound to MTs. Based on this role of L5 in
Eg5’s mechanochemical mechanism, we suggest that L5 in
some kinesin motors may be analogous to the 25/50 kDa
loop of the myosin motors. L5 and the 25/50 kDa loop are
in structurally similar locations on kinesin and myosin
motors, and both elements fine-tune the initial ADP release
event that leads to MT or actin activation.
L5 deletion alters the series of conformational changes
that take place in the Eg5 neck linker. In agreement with
previous results (14), we found that Eg5 transitions from
a pre-powerstroke neck linker conformation that is perpen-
dicular to the head, to a post-powerstroke, docked neck
linker conformation upon ADP release. Deletion of L5
blocks the pre-powerstroke conformation and forces Eg5 to
bind to MTs with its neck linker docked, regardless of the
nucleotide state. Together, these data suggest that L5, the
nucleotide pocket, and the neck linker undergo a series of
coupled conformational changes that integrate into the step-
ping mechanism of Eg5. High-resolution structural data will
be necessary to reveal how these elements are coupled to
elicit the conformational states and conformational changes
that have been identified here.SUPPORTING MATERIAL
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